Novel Medications for Opiate Detoxification - 4 - Full Text View

Novel Medications for Opiate Detoxification - 4

This study has been completed.

Sponsors and Collaborators:	National Institute on Drug Abuse (NIDA) VA Connecticut Healthcare System
Information provided by:	National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:	NCT00000279

Purpose

The purpose of this study is to evaluate novel medications for opiate detoxification.

Condition	Intervention	Phase
Opioid-Related Disorders Substance-Related Disorders	Drug: Clonidine	Phase II

Drug Information available for:

Clonidine Clonidine hydrochloride

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment

Official Title:	Novel Medications for Opiate Detoxification

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:

Estimated Enrollment:

Eligibility

Criteria

Please contact site for information.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000279

Locations


United States, Connecticut
	VA Connecticut Healthcare System
	New Haven, Connecticut, United States, 06519

Sponsors and Collaborators

National Institute on Drug Abuse (NIDA)

VA Connecticut Healthcare System

Investigators


Principal Investigator:	Thomas R Kosten, M.D.	VA Connecticut Healthcare System

More Information

Study ID Numbers:	NIDA-09250-4, P50-09250-4
First Received:	September 20, 1999
Last Updated:	June 23, 2005
ClinicalTrials.gov Identifier:	NCT00000279
Health Authority:	United States: Federal Government

Study placed in the following topic categories:

Mental Disorders

Clonidine

Substance-Related Disorders

Disorders of Environmental Origin

Opioid-Related Disorders

Additional relevant MeSH terms:

Pathologic Processes

Disease

ClinicalTrials.gov processed this record on December 03, 2008